Precision BioSciences (NASDAQ:DTIL) Upgraded to Outperform at BMO Capital Markets

BMO Capital Markets upgraded shares of Precision BioSciences (NASDAQ:DTIL) from a market perform rating to an outperform rating in a research note published on Friday, MarketBeat Ratings reports. They currently have $34.00 price objective on the stock.

Precision BioSciences Price Performance

Precision BioSciences stock opened at $5.70 on Friday. The firm has a market capitalization of $43.72 million, a P/E ratio of 95.02 and a beta of 1.41. Precision BioSciences has a one year low of $3.61 and a one year high of $19.43. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The business has a fifty day moving average price of $6.09 and a 200-day moving average price of $8.27.

Institutional Investors Weigh In On Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC boosted its position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,974 shares of the company’s stock after acquiring an additional 19,088 shares during the period. Geode Capital Management LLC owned 0.86% of Precision BioSciences worth $591,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.